RepoMed (Medizinische Hochschule Hannover)
Not a member yet
3024 research outputs found
Sort by
Comparison of accumulation and distribution of PEGylated and CD-47-functionalized magnetic nanoporous silica nanoparticles in an in vivo mouse model of implant infection
No full textDie zur Verfügung gestellten Rohdaten sind im Rahmen einer tierexperimentellen Studie erhoben (Genehmigungsnummer beim LAVES Nds.: 33.19-42502-04-20/3394) Es handelt sich um histologische Scorewerte, die nach dem im SI des Manuskripts verwendeten Score erhoben wurden und im Excel-Format zur Verfügung gestellt werden. Weiterhin werden mikroskopisch erhobene Messdaten zur Oberflächenanalyse der Implantate im Hinblick auf Partikelanreicherung (Messung der Fluoreszenzsignale in prozentualem Anteil der Gesamtimplantatfläche) ebenfalls im Excel-Format zur Verfügung gestellt. Die Daten wurden im Q3 2023 an der Medizinischen Hochschule Hannover (NIFE) erhoben
Ablation of the deubiquitinating enzyme cylindromatosis (CYLD) augments STAT1-mediated M1 macrophage polarization and fosters Staphylococcus aureus control
Get PDFIn atopic dermatitis (AD), lesional skin is frequently colonized by Staphylococcus aureus, which promotes clinical symptoms of the disease. The inflammatory milieu in the skin is characterized by a Th2 response, including M2 macrophages, which cannot eradicate S. aureus. Therefore, repolarization of macrophages toward the M1 phenotype may foster control of S. aureus. Our data show that the deubiquitinating enzyme cylindromatosis (CYLD) is strongly expressed in macrophages of AD patients and prevents the clearance of S. aureus. Mechanistically, CYLD impaired M1 macrophage polarization by K63-specific deubiquitination of STAT1 and activation of the NF-κB pathway via its interaction with TRAF6, NEMO, and RIPK2. Inhibition of STAT1 and NF-κB, independently, abolished the differences between S. aureus-infected CYLD-deficient and CYLD-competent M1 macrophages. Infection of Cyld-deficient and wild-type mice with S. aureus confirmed the protective CYLD function. Collectively, our study shows that CYLD impairs the control of S. aureus in macrophages of AD patients, identifying CYLD as a potential therapeutic target
Synaptic transmission in supragranular layers of the human cortex - comparative review of structure, function, and plasticity
Get PDFSynapses are the highly specialized connection sites between neurons enabling the establishment of complex neuronal networks. As highly plastic structures, synapses collocate both the transmission and storage of information, which is an essential prerequisite for learning and memory. Since synaptic deficits are associated with degenerative and neuropsychiatric diseases, it is essential to understand the mechanisms of synaptic plasticity. Throughout evolution, the human brain has developed distinct characteristics, such as supragranular expansion and enhanced long-range connectivity, suggesting an evolutionary specialization of synapses. Recent collaborative research, employing slice preparations obtained from neurosurgical resections of the human neocortex, has significantly advanced our understanding of the unique structural and functional properties of the human neocortex. This review investigates findings derived from diverse experimental methodologies, highlighting specific synaptic features. Focusing on synapses in supragranular layers, we discuss the distinctive synaptic structure, function, and mechanisms of plasticity that contribute to the unique circuitry of the adult human brain. Additionally, we outline emerging directions of research aimed at further elucidating the functionality of human cortical networks
Hochauflösende Immunzellphänotypisierung mittels spektraler Durchflusszytometrie im Rahmen der CD19-CAR-T-Zell-Therapie
Get PDFVergleichende Untersuchungen zu GATA3 und MYB in der kollagenen Spherulose und im Adenoid-zystischen Karzinom der Mamma
Get PDFBiomechanischer Vergleich von Einzelplatten- und Doppelplattenosteosynthesen bei Acromionfrakturen
Get PDFSwitch from Intravenous to Subcutaneous Immunoglobulin in CIDP and MMN: 12 Months Results from an Observational Study
Get PDFIntroduction Since 2018 subcutaneous immunoglobulin (SCIg) has been approved for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). However, comprehensive real-world data for long-term SCIg treatment are scarce for CIDP and especially for other immune-mediated neuropathies such as multifocal motor neuropathy (MMN). Methods In this observational study, 62 patients with CIDP and 13 with MMN were analyzed. Patients had been receiving regular intravenous immunoglobulin (IVIg) and transitioned to an equivalent weekly dose of SCIg. A comprehensive set of biographical, clinical, and paraclinical data were compared between the time of the switch and after 12 months. Results Subcutaneous administration was continued by 84% of the patients with CIDP and 77% of the patients with MMN for at least 12 months. Patients were clinically and electroneurographically stable over a period of 12 months under SCIg therapy and treatment satisfaction and preference was high. Nevertheless, intensified treatment especially by increasing the SCIg dose was necessary in a relevant proportion of both groups (31% of patients with CIDP and 40% of patients with MMN). The proportion of patients with concomitant autoimmune disease was higher in patients with CIDP with intensified treatment. Conclusions SCIg is an effective alternative maintenance treatment for patients with CIDP and MMN who have previously responded to IVIg. Switching to an equivalent weekly dose of SCIg as a replacement for monthly IVIg is both feasible and effective in most patients. Nevertheless, about one-quarter of patients require an increased dose of subcutaneous immunoglobulin, which is well tolerated and often preferred to allow continuation of this treatment modality
